Stockscreener 앱 받기
0.698
10.16%
-0.0789
시간 외 거래:
.68
-0.018
-2.58%
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Traws Pharma Company Profile & Introduction - Moomoo
Traws Pharma files prospectus for $139.2M mixed shelf offering - scanx.trade
TRAWTraws Pharma Inc Options - Finviz
Traws Pharma (TRAW) renews shelf for $139.2M unsold securities - Stock Titan
Price to book forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Price to sales forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Enterprise value to revenue forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Enterprise value to EBIT forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Traws Pharma, Inc. Actuals & Estimates (NASDAQ:TRAW) - TradingView
TRAW Forecast — Price Target — Prediction for 2027 - TradingView
Traws Pharma, Inc. Actuals & Estimates (FWB:0T20) - TradingView
0T20 Forecast — Price Target — Prediction for 2027 - TradingView
Traws Pharma stock falls as UK regulator delays key flu study - MSN
Traws Pharma Inc. (TRAW) Edges Higher With Modest Gain; Key Resistance at $0.90 in FocusSentiment Extreme - dars.gov.et
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - Sahm
Traws Pharma Inc (TRAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Traws Pharma updates influenza prophylaxis program guidance - grafa.com
Update on Traws Pharma (TRAW) Toxicology Data Submission - GuruFocus
Traws Pharma to Resubmit Influenza Prophylaxis Data to UK Regulators – Latest Update on Tivoxavir Marboxil Program 12 – Minichart - Minichart
Traws Pharma prepares new toxicology package for influenza drug - TipRanks
Traws Pharma (TRAW) plans Q3 2026 MHRA resubmission for Phase 2a flu study - Stock Titan
Why Did TRAW Stock Slump 28% After Hours? - Stocktwits
Traws Pharma Positions Long-Acting Antivirals for Influenza & Outbreak Threats as Sector Opportunities Expand - Streetwise Reports
Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program - Streetwise Reports
TRAWS PHARMA INC (TRAW) Stock Chart - ChartMill
Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Traws Pharma Inc (TRAW) Institutional Confidence - TradingKey
TRAW Downgraded by HC Wainwright & Co. -- Price Target Adjusted to $1.00 - GuruFocus
H.C. Wainwright Downgrades Traws Pharma(TRAW.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
Traws Pharma Inc (TRAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Traws Pharma Inc (TRAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Traws Pharma Inc (TRAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Traws Pharma Inc (TRAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Traws Pharma Inc (TRAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Traws Pharma (TRAW) Plunges Over 32%: Support Test and Liquidity ConcernsSentiment Extreme - newsline.com
Bandwidth, Traws Pharma and other big stocks moving lower in Monday's pre-market session - MSN
TRAW Downgraded by Ladenburg Thalmann -- Rating Changed to Neutr - GuruFocus
Traws Delays Influenza Study After UK Regulatory Setback - MyChesCo
Traws Pharma shares slide after UK regulator postpones influenza study - MSN
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Benzinga
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Micron, Nebius surge premarket; Traws Pharma tumbles By Investing.com - Investing.com India
Micron, Nebius surge premarket; Traws Pharma tumbles - Investing.com
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Yahoo Finance
Why is Traws Pharma stock tumbling today? By Investing.com - Investing.com Canada
Traws Pharma stock tumbles after UK regulator delays flu trial By Investing.com - Investing.com Canada
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
Traws Pharma Defers Phase 2a Human Influenza Study After UK MHRA Review, Advances Alternative Antiviral Candidates 1 – Minichart - Minichart
Traws Pharma (TRAW) Delays Phase 2a Trial of Tivoxavir Marboxil - GuruFocus
Why did TRAW stock slump 28% after hours? - MSN
1.17%
2.48%
자본화:
|
볼륨(24시간):